Entero Therapeutics Income Tax

Entero Therapeutics's income tax stands at $-13M as of June 2026. That compares with $11M in the prior-year period — down 221.4% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Entero Therapeutics reported $-13M in income tax versus $11M a year earlier — a 221.4% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $11M in the prior-year period — down 221.4% year over year. Sustained growth in income tax can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Entero Therapeutics's income tax evolved across reporting periods, while the comparison chart places ENTO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.